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Abstract
Background:  Germline mutations in the adenomatous polyposis gene (APC) result in familial
adenomatous polyposis (FAP). FAP is an autosomal dominantly inherited disorder predisposing to
colorectal cancer. Typical FAP is characterized by hundreds to thousands of colorectal adenomatous
polyps and by several extracolonic manifestations. An attenuated form of polyposis (AFAP) is
characterized by less than 100 adenomas and later onset of the disease.
Methods: Here, we analyzed the APC gene for germline mutations in 59 Czech and 15 Slovak FAP patients.
In addition, 50 apparently APC mutation negative Czech probands and 3 probands of Slovak origin were
screened for large deletions encompassing the APC  gene. Mutation screening was performed using
denaturing gradient gel electrophoresis and/or protein truncation test. DNA fragments showing an
aberrant electrophoretic banding pattern were sequenced. Screening for large deletions was performed
by multiplex ligation dependent probe amplification. The extent of deletions was analyzed using following
microsatellite markers: D5S299, D5S82, D5S134 and D5S346.
Results: In the set of Czech and Slovak patients, we identified 46 germline mutations among 74 unrelated
probands. Total mutation capture is 62,2% including large deletions. Thirty seven mutations were detected
in 49 patients presenting a classical FAP phenotype (75,5%) and 9 mutations in 25 patients with attenuated
FAP (36%). We report 20 novel germline APC mutations and 3 large deletions (6%) encompassing the
whole-gene deletions and/or exon 14 deletion. In the patients with novel mutations, correlations of the
mutation localization are discussed in context of the classical and/or attenuated phenotype of the disease.
Conclusion: The results of the molecular genetic testing are used both in the establishment of the
predictive diagnosis and in the clinical management of patients. In some cases this study has also shown
the difficulty to classify clinically between the classical and the attenuated form of FAP according to the
established criteria. Interfamilial and/or intrafamilial phenotype variability was also confirmed in some cases
which did not fit well with predicted genotype-phenotype correlation. All these findings have to be taken
into consideration both in the genetic counselling and in the patient care.
Published: 5 April 2007
BMC Medical Genetics 2007, 8:16 doi:10.1186/1471-2350-8-16
Received: 19 September 2006
Accepted: 5 April 2007
This article is available from: http://www.biomedcentral.com/1471-2350/8/16
© 2007 Stekrova et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2007, 8:16 http://www.biomedcentral.com/1471-2350/8/16
Page 2 of 9
(page number not for citation purposes)
Background
Germline mutations in the adenomatous polyposis coli
(APC) gene have been shown to result in the familial ade-
nomatous polyposis (FAP) syndrome. FAP (OMIM#
175100) is an autosomal dominantly inherited disorder
predisposing to colorectal cancer (CRC) and accounts for
1% of all CRC cases. Classical FAP is characterized by hun-
dreds to thousands of colorectal adenomatous polyps
developing during the second decade of life. Some of
these polyps progress to colorectal carcinoma if the whole
colon is not removed as a prophylactic intervention. Sev-
eral extracolonic manifestations are frequently presented
in FAP patients, including gastric and duodenal adeno-
mas, desmoid tumors, congenital hypertrophy of the reti-
nal pigment epithelium (CHRPE), osteomas, dental
abnormalities, epidermoid skin cysts and malignancies of
other organs. In addition to the classical form of FAP,
there are patients with an attenuated form of polyposis
(AFAP) characterized by less than 100 adenomas and later
onset of the disease. The APC gene located at chromo-
some 5q21 was identified in 1991 [1,2] and more than
600 germline mutations have been reported to date. The
majority of the APC germline mutations are frameshift,
nonsense or splice site mutations in the 5'half of the gene
resulting in a truncated protein. The APC protein is a part
of the wnt signalling pathway and contains several impor-
tant domains involving in processes such as cell cycle reg-
ulation, cell adhesion and apoptosis [3].
A number of screening methods have identified germline
APC mutations in 60–80% of all FAP patients [4]. Several
causations of the disease have been supposed in APC
mutation negative patients: (i) Recent studies have
revealed germline mutations in the base excision repair
MUTYH gene, leading to the MUTYH associated polyposis
(MAP) [[5,6] and [7]]. MAP is an autosomal recessive
form of polyposis with manifestation of AFAP in the
majority of the cases. (ii) In several studies, large deletions
have been found in the 5q21 region including the APC
gene [[8,9] and [10]]. These large deletions cannot be
detected by conventional mutation screening methods.
(iii) Mutations in both introns and regulatory regions of
the APC gene can escape the detection. (iv) Mutations in
not yet identified genes can be considered as the reason of
the disease.
The objectives of this report were: (i) to complete and to
characterize germline APC mutations in the Czech and
partly in the Slovak population; (ii) to asses whether the
large APC deletions might explain the FAP occurrence in a
part of Czech APC mutation negative patients; and (iii) to
determine genotype – phenotype associations.
Methods
Patients
Fifty nine unrelated Czech patients and 15 unrelated Slo-
vak patients with FAP were screened for APC germline
mutations. The set of patients included 36 Czech and 13
Slovak cases presenting with a classical FAP and 23 Czech
and 2 Slovak cases with an AFAP phenotype. All of them
came from various health institutions in Czech and Slo-
vak Republic and were referred on the basis of colono-
scopic findings and/or positive family history. The study
has been performed with the approval of Ethic Commit-
tee of the General University Hospital in Prague. Written
informed consent was obtained from each probands
before genetic testing. Together with our previous studies
[11,12] the set of 136 unrelated patients with FAP were
analyzed. Fifty apparently APC mutation negative Czech
probands from this set of patients (24 probands from this
paper and 26 patients from our previous studies) and 3
probands of Slovak origin were screened for large dele-
tions encompassing the APC gene.
Phenotype classification was based on two criteria: the
number of polyps and the age at diagnosis of FAP. The
phenotype was classified as typical FAP when the patient
presented with > 100 polyps in the second and/or third
decade of life with the ocurrence of CRC in or before the
fourth decade of life. The attenuated phenotype was char-
acterized by the occurrence of < 100 of polyps in the third
or fourth decade of life and later occurrence of the CRC.
Mutation screening
Genomic DNA was isolated from peripheral blood lym-
phocytes by the salting-out procedure [13]. The coding
region and intron – exon boundaries of the APC gene were
screened for mutations using DGGE (Denaturing Gradi-
ent Gel Electrophoresis) and/or PTT (Protein Truncation
Test). All patients were examined by very sensitive DGGE
method while only a small part of patients was examined
by PTT simultaneously. For DGGE analysis exons 1–15
were amplified using the set of GC-clamped primers and
PCR conditions as previously reported by Olschwang et
al. [14,15]. The protein truncation test (PTT) was per-
formed using TnT T7 Quick for PCR DNA system
(Promega). The test was used for screening of exon 15
which was amplified from genomic DNA in four overlap-
ping segments as described in detail by van der Luijt and
Meera Khan [16]. The coupled in vitro transcription-trans-
lation was performed in the presence of S35 – methionin.
After translation, the products were separated on 15%
SDS-polyacrylamide gel and detected by fluorography. All
DGGE and PTT fragments showing an aberrant electro-
phoretic banding pattern were sequenced in both direc-
tions using an automatic ABI Prism™ 310 Genetic
Analyzer (PE Applied Biosystem) in accordance with the
manufacturer's instructions. All mutations found wereBMC Medical Genetics 2007, 8:16 http://www.biomedcentral.com/1471-2350/8/16
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confirmed by repeated analysis of the second independ-
ent blood taking.
Screening for large deletions was performed by MLPA
(Multiplex Ligation Dependent Probe Amplification)
method using the MLPA kit SALSA P043 (MRC Holland).
Briefly, the protocol consists of DNA denaturation,
hybridisation of the SALSA probes to each target
sequence, followed by a ligation reaction. The target
sequences are amplified in a multiplex PCR and the PCR
products are separated on ABI Prism 310 Genetic Analyzer
accordance to the manufacturer's instruction.
To identify the extent of gross deletions we applied fol-
lowing microsatelite markers: D5S299, D5S82, D5S134
and D5S346. The sequence from centromere to telomere
is D5S299, D5S82, D5S134, the APC gene, D5S346, the
MCC gene. DNA was amplified by using following prim-
ers:
D5S299: S299F: GCTATTCTCTCAGGATCTTG
S299R: GTAAGCCAGGACAAGATGACA
D5S82: S82F: ATCAGAGTATCAGAATTTCT
S82R: CCCAATTGTATAGATTTAGAA
D5S134: S134F: ACATCTCCAATATAC-
CCCCCTCTCTCTTTC
S134R: TCCTCTGTGGTTGGTGAAATTGCACC
D5S346: S346F: ACTCACTCTAGTGATAAATCGGG
S346R: AGCAGATAAGACAGTATTACTAGTT
The PCR products were separated on 9% polyacrylamid
gel for 5 hours and the gels were stained with ethidium
bromide and photographed under UV light.
Results and discussion
Mutation analysis of the APC coding region resulted in the
identification of 46 pathogenic mutations including large
deletions in 74 unrelated Czech and Slovak patients
(62,2%). Thirty seven germline mutations were detected
in 49 patients with classical FAP (75,5%) and 9 mutations
in 25 patients with AFAP (36%). Twenty mutations were
novel. The summary of the mutations identified in this set
of Czech and Slovak patients is given in Tab. 1.
Our mutation detection rate is consistent with previous
reports. Using standard mutation analysis, 20–30% of
classical FAP patients have no detectable APC mutation.
The detection rate can be increased using other tests such
as MLPA analysis, MAMA (Monoallelic Mutation Analy-
sis) and so on. In our study, it is quite likely that muta-
tions in regulation and/or in noncoding regions are
missed. It was shown that newer diagnostic method such
as MAMA [17] combined with standard genetic testing
can identify APC mutations in > 95% FAP patients. Using
this method, two APC alleles can be examined independ-
ently. Reduced expression in mutant allele can be demon-
strated at protein level. In a set of APC mutation negative
patient, biallelic mutations in MUTYH gene can also be
responsible for polyposis same as mutations in not yet
identified genes.
In 59 unrelated Czech patients, standard mutation analy-
sis of the APC coding region revealed 35 germline muta-
tions. Among the 36 probands presenting a classical FAP
phenotype,  APC  point mutations were detected in 26
patients (72,2%). Nine mutations (9/23 probands) were
identified in patients with AFAP (39,1%). A total of 26 dif-
ferent mutations were detected, including 16 novel ones
(detected in 17 patients), not previously reported. Of the
16 newly described mutations, fourteen were truncating
and two ones affected donor and/or acceptor splice site.
Using MLPA analysis, deletion screening revealed large
deletions in 3 of the 50 Czech patients (6%) with no APC
point mutation. Together with our previous studies
[11,12] ninety two germline mutations including large
deletions were detected in 136 unrelated Czech patients,
thus the mutation detection rate was 67,6 %. In this com-
bined sample, the mutation detection rate in classical FAP
is 77,2% (78/101) and 40% (14/35) in attenuated FAP. In
accordance with previous studies, the most common
mutation was the codon 1309 5 bp deletion (10%) [4].
Substitution c.2805C>A at codon 935 (7%) was also quite
frequent. However the frequency of the deletion at codon
1061 seems to be lover (3%) than referred data [3].
In a set of Slovak probands, eight germline mutations
were discovered in 13 patients with classical FAP (61,5%),
including four novel mutations, not previously reported
(Tab. 1). No mutation was detected in 2 patients with
AFAP. Large deletions were screened in 3 Slovak FAP
patients with no APC  point mutation. MLPA analysis
revealed no large deletion.
Novel mutations
Out of the 17 Czech patients with identified novel muta-
tions, 9 patients presented a classical form of FAP and 8
patients suffered from an attenuated form of the disease.
In concordance with published reports, the AFAP pheno-
type was associated with mutations in exons 2, 3, 4 and 9
(Tab. 1). Different phenotypes were found in two unre-
lated patients (probands 145 and 203) with the same 4 bp
deletion in exon 15 (Fig. 1). The proband 203 presented
classical FAP with early onset of polyposis and colorectalBMC Medical Genetics 2007, 8:16 http://www.biomedcentral.com/1471-2350/8/16
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cancer while the proband 145 was diagnosed for polypo-
sis in the fifth decade of life and he underwent the colec-
tomy at the age 58. His mother was diagnosed for CRC at
the age of 61 and the diagnosis of CRC occurred also in his
3 brothers and his sister (at the age of 39, 47, 68 and 31
respectively). The intrafamilial variations in the FAP phe-
notype are known and it is supposed that modifying genes
and/or environmental factors could play a role in deter-
mining the phenotype.
The mutation found in the proband 147 (c.220G>T) leads
to a creation of stop codon (p.Glu74X) keeping the dimer-
ization domain in the APC protein. However, this single
base substitution affected the last nucleotide of the exon 2
and consequently the aberrant splicing cannot be
excluded (77% likelihood). The proband is classified to
have AFAP because first symptoms displayed as CRC at 62
of age. This type of mutation was also demonstrated in his
sister (60 years old), both brothers (54 and 62 years old)
Table 1: APC germline mutations in Czech and Slovak FAP patients
FAMILY PHENOTYPE NUCLEOTIDE CHANGE CONSEQUENCE REFERENCE
147 AFAP c.220G>T p.Glu74X (*) Current paper
229 AFAP c.230T>G p.Leu77X Current paper
177 AFAP c.288_289insCC p.Gly97ProfsX29 Current paper
176 AFAP c.505_509delATAGA p.Ile169X Current paper
150 FAP c.517_520delCCTT p.Pro173X [20]
179 AFAP (V) c.531+1G>T * Current paper
155 FAP c.637C>T p.Arg213X [25]
208 FAP c.637C>T p.Arg213X [25]
164 FAP c.645+1G>T * Current paper
144 FAP c.646C>T p.Arg216X [26]
162 FAP c.646C>T p.Arg216X [26]
174 FAP c.646C>T p.Arg216X [26]
S8 FAP c.646C>T p.Arg216X [26]
S7 FAP (L) c.759_787del29 p.His255ArgfsX11 Current paper
S14 FAP (L) c.834+1G>A * [14]
226 FAP c.880delT p.Ser294LeufsX11 Current paper
211 AFAP c.994C>T p.Arg332X [27]
262 AFAP c.1102_1103delGT p.Val368IlefsX9 Current paper
220 AFAP c.1111G>T p.Gly371X Current paper
202 FAP c.1251delT p.Cys417TrpfsX37 Current paper
215 FAP (L) c.1284delA p.Glu428AspfsX26 Current paper
S16 FAP c.1370C>G p.Ser457X Current paper
173 FAP c.1411G>T p.Gly471X [12]
S1 FAP c.1624C>T p.Gln542X Current paper
157 FAP c.2024delC p.Thr675LysfsX2 Current paper
145 AFAP (V) c.2031_2034delCAGT p.Ser678MetfsX39 Current paper
203 FAP c.2031_2034delCAGT p.Ser678MetfsX39 Current paper
233 FAP c.2390delG p.Gly797ValfsX23 Current paper
171 FAP c.2626C>T p.Arg876X [28]
S15 FAP (L) c.2800_2803delACTT p.Tyr935IlefsX19 [29]
195 FAP c.2805C>A p.Tyr935X [30]
242 FAP c.2805C>A p.Tyr935X [30]
206 FAP c.2977_2980dupAAGT p.Phe994X Current paper
S10 FAP c.3413delA p.Asp1138ValfsX27 Current paper
153 FAP c.3471_3474delGAGA p.Glu1157AspfsX7 [31]
181 FAP c.3471_3474delGAGA p.Glu1157AspfsX7 [31]
240 FAP c.3513dupT p.His1172SerfsX7 Current paper
225 FAP c.3786T>A p.Tyr1262X [4]
183 FAP c.3927_3931delAAAGA p.Glu1309AspfsX4 [25]
205 FAP c.3927_3931delAAAGA p.Glu1309AspfsX4 [25]
218 FAP c.3927_3931delAAAGA p.Glu1309AspfsX4 [25]
248 FAP c.3927_3931delAAAGA p.Glu1309AspfsX4 [25]
S12 FAP c.4666dupA p.Thr1556AsnfsX3 [32]
cDNA numbering is based on reference sequence: GenBank NM_000038, +1 corresponds to the A of the ATG translation initiation codon.
Novel mutations in boldface type. S – Patient of Slovak origin, V – intrafamilial variable phenotype, L – late onset of the disease; > 100 polyps. * 
Mutations can affect splicingBMC Medical Genetics 2007, 8:16 http://www.biomedcentral.com/1471-2350/8/16
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and two daughters (35 and 38 years old). Now, colono-
scopic examinations are performed in his relatives.
Patients 229 and 177 with mutation in exon 2 and 3
respectively presented with an attenuated phenotype
(with about 100 adenomas diagnosed at age of 62 and 63
years respectively and with no evidence of carcinoma).
In the case of the proband 179, a single base pair change
at the conserved splice donor +1 position of intron 4
(c.531+1G>T) was identified predicting the splice defect.
The proband is classified as an attenuated form of FAP on
the basis of the polyp number: only three polyps devel-
oped when the proband was 22 years old. However, his
brother can display a phenotype with more likely interme-
diate features between the attenuated and classic forms of
FAP with respect to the onset of the disease and number
of polyps: he was diagnosed for polyp occurrence when he
was 15 years old and he developed < 100 polyps at this
age. The proband's father was diagnosed for colorectal
cancer at the age 41 and he agreed for colectomy. Two
additional reports describe mutations in intron 4 of the
APC gene that result in the splice defect. An insertion of a
single thymidine (c.531 +2_531 +3insT) [18] and two
substitutions at the donor splice site and in its neighbour-
hood (c.531+1G>A, c.531+5G>C) [19] were identified in
American and in two Finish families. The phenotypes of
these patients are consistent with the attenuated FAP phe-
notype. Our and previous results confirmed the sugges-
tion that this APC region is prone to intronic mutations
leading to splice defect [18].
A phenotype of our proband 179 and his brother resem-
bles the recently described AFAP syndrome with atypical
disease course caused by a CCTT deletion in exon 4
(codon 173) [20]. In this case, the proband revealed a low
number of polyps (approximately 30) at the age of 17 and
his father and grandfather died due to colorectal cancer at
35 and 40 years of age. Our proband (176) with the dele-
tion in exon 4 presented attenuated form of FAP with the
onset of the disease during the fifth decade of life (diag-
nosed for CRC at age 47). His son developed about 100
polyps at age 21 years. However, the phenotype of the
proband (150) showing the same mutation described by
Plawski [20] corresponds rather to classic course of FAP
with occurrence CRC at age of 37. Unfortunately, the
number of polyps is unknown. An additional report
describes a nonsense mutation in codon 161 (exon 4)
[21] leading also to a phenotype with features between
classic and attenuated forms of FAP (later onset and more
than 100 colorectal polyps). Classical form of FAP is
described in two patients with mutations at the invariant
splice acceptor site of exon 4 [24] . Both patients pre-
sented with > 100 adenomas at age of 32 – 35 years. Muta-
tions at 5'end of the APC gene (especially in exons 3 and
4) were originally described to be associated with the
attenuated phenotype. However, it appears that the muta-
tions located in exon and intron 4 lead to the greater phe-
notype variability resulting in a difficult classification
between classical and attenuated forms of the disease.
The patients with germline APC mutations in the alterna-
tively spliced exon 9 (probands 262, 220) have a pheno-
Analysis of APC germline mutations of exon 15A Figure 1
Analysis of APC germline mutations of exon 15A. a. Denatur-
ing Gradient Gel Electrophoresis PCR products of exon15A 
of FAP patients. Lane 3 represents heterozygous proband of 
the family 145. b. Sequencing pattern of part of the exon 15A 
(forward) in proband of the family 145 with heterozygous 
deletion CAGT at nucleotide position 2031_2034 
(p.Ser678MetfsX39) and control.BMC Medical Genetics 2007, 8:16 http://www.biomedcentral.com/1471-2350/8/16
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type of attenuated FAP (Fig. 2a). The proband 220 is a
woman which developed < 100 polyps when she was 36
years old and then she is classified as AFAP. Her sister was
diagnosed for polyp occurrence (< 100) at the age of 40
and her father was diagnosed for colorectal cancer at the
age of 50. The patient 262 was found to have about 100
polyps at the age of 54. He had no cancer in the colon and
his family history was negative. Variable phenotypes in
the alternatively spliced region of exon 9 are described by
Sieber et al. [22]. They analysed phenotypes and genetic
pathways in attenuated FAP associated with germline
mutations in the 5', 3'and exon 9 of the APC gene. Their
genetic analysis revealed a requirement for "three hits" in
at least some AFAP adenomas. In exon 9 mutant patients,
the third hits were more frequent in adenomas than in
5'and/or 3'mutant patients.
The patients 202 and 215 with mutations localized in the
regularly spliced region of exon 9 (Fig. 2b) are expected to
present with classical FAP. Indeed, the patient 202 devel-
oped thousands of polyps at the age 30 and underwent
total colectomy without evidence of cancer. The disease
picture of the patient 215 is not so unambiguous. He was
diagnosed for both polyps (hundreds) and cancer at the
age 42. However, the later diagnosis can be connected
with his negative family history or later occurrence of
symptoms while polyp development could start several
years earlier.
The possible explanation of variable FAP phenotypes may
be other modifying genes, epigenetic mechanisms and
environmental factors. Currently, reasons of attenuated
course of the disease and a role of the AUG (start codon)
at codon 184 [23] are searched and discussed [22].
The remainder patients with novel germline mutations in
intron 5 (proband 164), exon 8 (proband 226) and 15
(probands 157, 233, 206 and 240) presented with the
classical form of FAP with the > 100 polyps developed in
the second and/or third decade of life (Tab. 1).
In a set of Slovak probands four novel mutations were dis-
covered (Tab. 1). The newly described mutations were
frameshift or nonsense in the 4 cases resulting in a trun-
cated APC protein (probands S7, S16, S1 and S10). The
mutation analysis revealed two DNA variations in the
proband S10: the frame shift mutation
(p.Asp1138ValfsX27) resulting in a truncating protein
and one silent mutation which affected the first nucle-
otide of exon 15 (c.1959G>A, p.Arg653Arg) predicting
the possibility of the aberrant splicing of the acceptor
splice site in intron 14. However, this silent substitution
rather represents a rare polymorphism because recently it
was shown not to influence splicing on mRNA level [24].
All of the patients with the novel mutations presented the
classical form of the disease in accordance with a localiza-
tion of mutations except for the proband S7. This patient
has the 29 bp deletion in exon 7 resulting in frameshift
and premature stop codon. His phenotype varies between
the FAP and AFAP with thousands of polyps without car-
cinoma but with later onset (at age 37) of the disease. This
conclusion is supported by clinical pictures in his rela-
tives. First symptoms occurred at 51 years of age in his
father (diagnosis of CRC and thousands of polyps) and
the similar manifestations occurred in his two brothers
(CRC and thousands of polyps at 52 and 53 years of age
respectively).
Large APC deletions
Using MLPA analysis of 50 (24 probands from this paper
and 26 patients from our previous studies) unrelated
Czech and 3 Slovak FAP patients with no APC point muta-
tion was performed. MLPA analysis revealed large dele-
tions in 3 of the 50 Czech patients (6%). No large deletion
was detected in Slovak patients. In Czech population, the
frequency of large deletions appears to be slightly lower
than recently published data [9,10]. Of the three dele-
tions, the two whole-gene deletions including the pro-
moter region (probands 43 and 54) and one exon 14
deletion were found. Microsatellite analysis was under-
taken to determine the extent of the whole-gene deletions.
On the basis of this analysis we can conclude that the dis-
tal breakpoint is situated between APC and the region of
the D5S346, MCC gene and the deletion at the proximal
site does not interfere in the region of the D5S299. The
precise localization of the deletion breakpoints has not
been finished. All three large deletions were identified in
the set of patients with classical FAP, and not in patients
suspected of AFAP confirming recently published data
[9,10]. The FAP phenotype was quite classical with a hun-
dred to thousand colorectal adenomas, CHRPE and with
development of desmoid tumours and osteomas.
Conclusion
In our study both novel and reported APC mutations were
identified in Czech and Slovak FAP patients. The results of
the molecular genetic testing are used both in the estab-
lishment of the predictive diagnosis and in the clinical
management of patients. In some cases this study has also
shown the difficulty to classify clinically between the clas-
sical and the attenuated form of FAP according to the
established criteria: some clinical manifestations in a
patient are characteristic for classical FAP and another fea-
ture resembles attenuated FAP in the same patient. Inter-
familial and/or intrafamilial phenotype variability was
also confirmed in some cases which did not fit well with
predicted genotype-phenotype correlation. All these find-
ings have to be taken into consideration both in the
genetic counselling and in the patient care.BMC Medical Genetics 2007, 8:16 http://www.biomedcentral.com/1471-2350/8/16
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Analysis of APC germline mutations of exon 9 Figure 2
Analysis of APC germline mutations of exon 9. a. Sequencing pattern of alternatively spliced part of the exon 9 (forward) in 
proband of the family 220 (AFAP phenotype) with heterozygous substitution G>T at nucleotide position 1111 (p.Gly371X) and 
control b. Sequencing pattern of part in the regularly spliced region of the exon 9 (forward) in proband of the family 202 (FAP 
phenotype) with heterozygous deletion T at nucleotide position 1251 (p.Cys417TrpfsX37) and control.BMC Medical Genetics 2007, 8:16 http://www.biomedcentral.com/1471-2350/8/16
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